Is this proof we're living in a ‘simulated universe'? Scientist's theory points to possible clue
Are we living in 'The Matrix' in real life?
In the 1999 science-fiction film, Neo discovers that the universe is a simulation — but one scientist believes that the idea isn't all fiction.
Dr. Melvin Vopson, an associate professor in physics at the University of Portsmouth in the UK, believes that gravity is a sign that we are living in a virtual simulation and the universe is the 'ultimate computer,' he alleged in a new paper.
Advertisement
4 Dr. Melvin Vopson believes that the concept in 'The Matrix' isn't all fiction.
Warner Bros/Village Roadshow Pictures/Kobal / Shutterstock
In the research, published in AIP Advances, Vopson proposes the idea that gravity isn't just a 'pull' — it's actually something that occurs when the universe is trying to keep its data organized.
Forcing objects with mass to be pulled toward the Earth's core is similar to how computers compress code, Vopson claimed.
Advertisement
4 Keanu Reeves in 'The Matrix.'
Everett Collection
He added in the paper that gravitational pull is an 'example of data compression and computational optimization in our universe, which supports the possibility of a simulated or computational universe.'
'The universe evolves in a way that the information content in it is compressed, optimized and organized – just as computers and computer code do,' he told the Daily Mail. 'Hence, gravity appears to be another process of data compression in a possibly simulated universe.'
The gravitational attraction helps reduce 'information entropy,' which essentially means how much information there is in an object in any given space, the study alleges.
Advertisement
4 In the 1999 science-fiction film, Neo discovers that the universe is a simulation.
Warner Bros/Village Roadshow Pictures/Kobal / Shutterstock
Gravity plays many roles in space, including the building of galaxies, putting planets into orbit around stars and influencing the motion of nearby objects. So, in Vopson's theory, these objects may be pulled together because the universe is simply trying to keep everything clean and compressed.
'To put it simply, it is easier to compute all the properties and characteristics of a single object in space, rather than multiple objects,' he told the Daily Mail. 'That is why objects in space are pulled together.'
4 The typical evolution of matter in the universe under gravitational attraction.
AIP Advances
Advertisement
His belief stems from the concept of entropy in information theory, which he has argued in a previous paper.
'A super complex universe like ours, if it were a simulation, would require a built-in data optimization and compression in order to reduce the computational power and the data storage requirements to run the simulation,' he explained in a piece for The Conversation in 2023.
'This is exactly what we are observing all around us, including in digital data, biological systems, mathematical symmetries and the entire universe.'
This time, rather, Vopson focused on gravity rather than biological systems.
'My findings in this study fit with the thought that the universe might work like a giant computer, or our reality is a simulated construct,' Vopson explained in a statement.
'Just like computers try to save space and run more efficiently, the universe might be doing the same. It's a new way to think about gravity – not just as a pull, but as something that happens when the universe is trying to stay organized.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 days ago
- Yahoo
A bottlenose dolphin? Or Tursiops truncatus? Why biologists give organisms those strange, unpronounceable names
Most people would call it a 'field mouse,' but a scientist would ask, 'Was it Peromyscus maniculatus? Or Peromyscus leucopus?' Scientists use a system of complicated-sounding names to refer to everyday creatures, a practice heavily lampooned in the Warner Bros. cartoons featuring the Road Runner and Wile E. Coyote – or, respectively, Accelleratii incredibus and Carnivorous vulgaris. As a biologist, I use these seemingly odd names myself and help my students learn them. For most people it's a huge effort, like learning a second language. That's because it is. The science of naming and classifying organisms is called taxonomy. Scientists do this so they can be as precise as possible when discussing living things. The first word in an organism's name is its genus, which is a group of related species, such as Panthera for lions, tigers and leopards. The second word is the specific name identifying the species, usually defined as a population that can reproduce only with each other, such as Panthera leo for lion. Every two-word combination must be unique. Called binomial nomenclature, this naming system was popularized by Swedish naturalist Carl Linnaeus in the 1700s. So, humans are Homo sapiens, the red maple Acer rubrum, garlic Allium sativum, and the eastern spotted skunk Spilogale putorius. Today, biologists maintain huge databases containing the taxonomic names of plants, animals, fungi and other organisms. For instance, one of these databases – the Open Tree of Life project – includes over 2.3 million species. The scientist who discovers a species usually names it by publishing a formal description in a peer-reviewed journal. From there, the name makes its way into the databases. From then on, scientists always use that name for the organism, even if it turns out to be misleading. For example, many fossils were originally given names containing the Greek root 'saur,' which means lizard – even though paleontologists later realized dinosaurs were not lizards. To most people, these names sound inscrutable. Particularly nowadays, as science becomes more open and accessible to everyone, such arcane vocabulary can come across as old-fashioned and elitist. Given the current backlash against 'elites' and 'experts' in every field, that's a serious charge. But in a roundabout way, this seemingly exclusive practice is really a story of inclusiveness. As modern science began taking shape in Europe during the 1600s, scientists had a problem. They wanted to read and be read by others, but language got in the way. French scientists couldn't read Swedish, Swedes couldn't read Italian, and Italians couldn't read German. Also, writing about plants and animals posed a particular challenge: Many species had common names that could vary from place to place, and some common names might apply to multiple species. Scientists needed a way to be precise and consistent when referring to species, so that everyone could understand each other. To sidestep the language issue, scientists of the era mostly published their work in classical Latin. Back then, everyone learned it – at least every European man wealthy enough to attend school and become a scientist. Others published in classical Greek, also widely taught. By sticking with these more universally known languages, early scientists made sure that science was accessible to as many of their peers as possible. By the late 1700s and 1800s, translation services were broadly available, so naturalists such as Georges Cuvier could write in his native French, and Charles Darwin in his native English. Today, English has become the de facto language for science, so most scientists publish in English regardless of their native tongue. So why continue to use Latin and Greek names today? Taxonomists do it partly out of tradition, but partly because the terminology is still useful. Even without seeing a photo of the animal, a biologist might work out that Geomys bursarius – 'earth-mouse with a pouch' – was a pocket gopher. Or that Reithrodontomys fulvescens – 'groove-toothed mouse that is yellow' – is a yellow mouse with grooves on its incisors. Although taxonomists still largely adhere to the naming principles of Linnaeus, new scientific names are more and more frequently derived from non-European languages. For example, a chicken-size dinosaur discovered and named in China is called Yi qi, meaning 'strange wing' in Mandarin. Some of the more recent names are touched by whimsy, with a few honoring politicians and celebrities. Etheostoma obama is a spangled darter named after the 44th U.S. president; the Swift twisted-claw millipede – Nannaria swiftae – is named after pop star Taylor Swift. With so much of Earth's biodiversity yet to be discovered and named, remember that names are just names. What we call these species often reflects our own values and perspectives. In the future, another language – or no language at all – might rise to dominance. Artificial intelligence may act as a universal translator. This possibility would let everyone publish and read science in their own language. Predicting how technology will change our relationship with terminology is challenging, but the need for precise scientific language, including the names of species, will never go away. This article is republished from The Conversation, a nonprofit, independent news organization bringing you facts and trustworthy analysis to help you make sense of our complex world. It was written by: Nicholas Green, Kennesaw State University Read more: How many types of insects are there in the world? Thousands of undiscovered mammal species may be hidden in plain sight, new research finds Scientists discover five new species of black corals living thousands of feet below the ocean surface near the Great Barrier Reef Nicholas Green does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
Associated Press
29-05-2025
- Associated Press
Introducing Norton Neo: The Browser Ahead of You
From Netscape Navigator to Google Chrome: 30 Years of Browser Evolution Thirty years ago, Netscape went public and helped launch the internet era. Its browser, Netscape Navigator, led the way and laid the foundation for how billions of people would access the web. As the internet grew, so did the competition. Internet Explorer soon surged ahead, at one point holding over 90% of the market share and becoming the default gateway to the online world. But as applications became more dynamic and interactive (with digital platforms like Gmail, Facebook and Google Maps), IE struggled to keep up. These apps ran slowly and fell short of expectations. Then, Chrome emerged. It wasn't just incrementally better; it delivered 10 times the leap in performance for JavaScript-heavy applications. The improvement was undeniable. What seemed impossible — taking market share from IE — became inevitable, simply because Chrome made life 10 times better for the new internet experience. Fast forward to 2024, I joined Gen with a clear vision: Generative AI will redefine how consumers enter the digital world. Fittingly, my team has been working in the same office building where Netscape Navigator team made history, and it's here that we're carrying the torch to re-invent the browser for the AI era. Browsers Were Due for a Revolution. This is it. Today, we face a new, equally urgent pain point. The internet is no longer only a collection of websites. It's a fragmented universe of emails, documents, messages, meetings, tabs and cloud and web services scattered across tabs and accounts. We're drowning in information and switching contexts all day, yet struggling to get to what really matters fast. We don't need more information. We need fewer barriers. Less friction. Less cognitive overhead. More clarity. More outcomes. It's time for a new leap. Introducing Norton Neo That leap begins with Norton Neo — the world's first Safe AI-native browser. Norton Neo is built for a world where information is abundant, but focus is scarce. Where apps multiply, but time doesn't. With Neo, AI works seamlessly within your browser — no app switching, no tab overload. Just a proactive assistant powered by ChatGPT-level intelligence you can trust. Neo doesn't just respond — it anticipates. Today's launch is more than a new product. It's a statement: That the browser, one of the most-used apps on every computer — is overdue for reinvention, and that meaningful innovation can come from an S&P 500 company like Gen. Our goal here is simple: to build technology that helps people live more freely and confidently online. During this early access phase of Norton Neo, we're excited to hear what people think — your feedback will help shape what Neo becomes. We're listening, we're learning and we're focused on creating a smarter, safer digital world for everyone. This is just the beginning — not only of a new product, but a new category. Here's what you can expect with Norton Neo in the future. A New Vision for the Way We Browse 1. AI-Native: Empowering You Behind the Scenes Most AI tools today feel disjointed. You jump between apps. You paste prompts. You reword questions. Neo plans to change that. Neo will bring you the intelligence of ChatGPT — but no heavy prompts, no friction, no effort. It works in the background, offering proactive support when you need it. 2. Reinventing Search: A Browser That Connects Your Entire Digital World The traditional browser searched the public web. The new browser searches and helps manage your entire digital world. Looking for a document you saw last week? Neo retrieves it. Need a meeting summary? It's already parsed and ready to go. Why leave the tab open when your AI can remember and find everything for you? Why juggle 100 tabs like it's still the last decade? This isn't just about finding faster as Google Chrome has been doing it for more than a decade. It's about discovering smarter. Neo turns chaos into clarity by being more proactive and more personalized. 3. More Than a Browser but a Doer The next browser isn't a tool. It's a partner, an agent or a personal assistant. It can take action, finish tasks and bring you clarity. The more capable your AI, the more powerful your experience. Need to cancel a reservation, send a follow-up email or fill out a form? Neo handles it or prepares for you. From routine tasks to complex decisions, it's the browser that works with you — quietly, intelligently and safely. It's not just faster browsing; it's smarter living. 4. Built-in Protection from the Start Neo is built on Chromium, so it works with the extensions you already rely on. But what makes it different is what's built in: always-on protection, free ad blocking and trusted safe browsing — all powered by Norton's decades of security expertise. As AI becomes more powerful, trust matters more than ever for everyday people like you and me. That's why Neo brings intelligence to your browser with protection built in from the very start. Backed by a brand known for putting people first, Neo is designed to help you explore what's next with confidence. You don't have to trade intelligence for security or speed for peace of mind. With Neo, smart is secure and your protection is always on. A Paradigm Shift in the Making Just like Netscape Navigator, Internet Explorer and Google Chrome defined their generations, Norton Neo is here to define the next one. This isn't about another upgrade. This is about a complete reinvention of how you live and work online. A shift from reactive browsing to anticipatory companionship. From clutter and fragmentation to clarity and flow. From Information to Intelligence to Outcome. It's about breaking down the barriers between you and your potential. It's about trust, intelligence, simplicity — and yes, a little bit of magic. The age of reactive browsing is ending. The age of the browser ahead of you is just beginning. Learn more about the First Safe AI-native Browser here: Visit 3BL Media to see more multimedia and stories from Gen Digital Inc.
Yahoo
27-05-2025
- Yahoo
Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma
Novel combination with efti has met the trial's primary endpoint of tumour hyalinization/fibrosis in the neoadjuvant setting for patients with resectable soft tissue sarcoma Detailed results are planned for presentation at a future medical meeting SYDNEY, AUSTRALIA, May 27, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ('Immutep' or 'the Company'), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces the investigator-initiated EFTISARC-NEO Phase II trial evaluating eftilagimod alfa (efti) with radiotherapy plus KEYTRUDA® (pembrolizumab) in the neoadjuvant setting for resectable soft tissue sarcoma (STS) has met its primary endpoint. The novel combination significantly exceeded the study's prespecified median of 35% tumour hyalinization/fibrosis versus 15% for historical data from radiotherapy alone in patients with resectable soft tissue sarcoma (STS). Tumour hyalinization/fibrosis is an early surrogate endpoint at the time of surgical resection that has been associated with improved overall survival and recurrence-free survival for STS patients.1,2 The trial's investigators at the Maria Skłodowska-Curie National Research Institute of Oncology (MSCNRIO) in Warsaw, the national reference centre for STS in Poland, plan to present detailed results from the study at a future medical meeting. Katarzyna Kozak, M.D., Ph.D., and Paweł Sobczuk, M.D., Ph.D., medical oncologists at the Department of Soft Tissue/Bone Sarcoma and Melanoma at MSCNRIO and the trial's principal investigators, said: 'It is very encouraging to see the chemotherapy-free combination with efti far exceed the ambitious target we initially set for the trial's primary endpoint in resectable soft tissue sarcoma. These results support our belief that efti's activation of antigen-presenting cells, and in turn a broad adaptive and innate immune response, helps transform the immunosuppressed tumour microenvironment of soft tissue sarcomas leading to strong anti-cancer efficacy. There remains a very high unmet need in this aggressive orphan cancer indication and we look forward to presenting detailed results at a medical meeting later this year.' As previously announced at the Connective Tissue Oncology Society (CTOS) Annual Meeting in November 2024, the combination therapy demonstrated significant efficacy with a median of 50% tumour hyalinization/fibrosis in a preliminary analysis of 21 patients with resectable STS available for primary endpoint assessment. The EFTISARC-NEO study, which is primarily funded with a grant from the Polish government awarded by the Polish Medical Research Agency program, subsequently completed enrolment of 40 patients in January 2025. STS is an orphan disease with high unmet medical need and a poor prognosis for patients. The incidence of STS varies in different regions globally. In the United States, the number of new STS cases in 2025 is estimated to be ~13,520 with ~5,420 deaths, according to the American Cancer Society.3 For more information on EFTISARC-NEO, visit (NCT06128863). About Eftilagimod Alfa (efti)Efti is Immutep's proprietary soluble LAG-3 protein and MHC Class II agonist that stimulates both innate and adaptive immunity for the treatment of cancer. As a first-in-class antigen presenting cell (APC) activator, efti binds to MHC (major histocompatibility complex) Class II molecules on APC leading to activation and proliferation of CD8+ cytotoxic T cells, CD4+ helper T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological molecules like IFN-ƴ and CXCL10 that further boost the immune system's ability to fight cancer. Efti is under evaluation for a variety of solid tumours including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables various combinations, including with anti-PD-[L]1 immunotherapy and/or chemotherapy. Efti has received Fast Track designation in first line HNSCC and in first line NSCLC from the United States Food and Drug Administration (FDA). About ImmutepImmutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3's ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit 1. Schaefer IM et al. Histologic Appearance After Preoperative Radiation Therapy for Soft Tissue Sarcoma: Assessment of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group Response Score. Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):375-383. doi: 10.1016/ Epub 2017 Feb 24. PMID: 28463157.2. Rao SR et al. Extent of tumor fibrosis/hyalinization and infarction following neoadjuvant radiation therapy is associated with improved survival in patients with soft-tissue sarcoma. Cancer Med. 2022 Jan;11(1):194-206. doi: 10.1002/cam4.4428. Epub 2021 Nov 27. PMID: 34837341; PMCID: PMC8704179.3. American Cancer Society statistics: KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Australian Investors/Media:Catherine Strong, Sodali & Co.+61 (0)406 759 268; U.S. Media:Chris Basta, VP, Investor Relations and Corporate Communications+1 (631) 318 4000; in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
